Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Nu-Med Plus (NUMD) EPS (Weighted Average and Diluted) (2016 - 2025)

Nu-Med Plus' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.0 for Q4 2021.

  • On a quarterly basis, EPS (Weighted Average and Diluted) changed N/A to -$0.0 in Q4 2021 year-over-year; TTM through Dec 2021 was -$0.0, a N/A change, with the full-year FY2021 number at -$0.01, changed N/A from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.0 in Q4 2021 for Nu-Med Plus, down from -$0.0 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for NUMD hit a ceiling of $0.05 in Q4 2017 and a floor of -$0.01 in Q3 2018.
  • Historically, EPS (Weighted Average and Diluted) has averaged $0.01 across 3 years, with a median of -$0.0 in 2017.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 371.41% in 2017 and later tumbled 476.5% in 2018.
  • Tracing NUMD's EPS (Weighted Average and Diluted) over 3 years: stood at $0.05 in 2017, then tumbled by 118.42% to -$0.01 in 2018, then skyrocketed by 84.69% to -$0.0 in 2021.
  • Business Quant data shows EPS (Weighted Average and Diluted) for NUMD at -$0.0 in Q4 2021, -$0.0 in Q3 2021, and -$0.0 in Q2 2021.